The Future of Alzheimer’s Treatments
Alzheimer’s is a complex, debilitating disease that affects over 55 million people, yet there is no cure. It’s difficult to see people we love struggle so much — and it’s even more difficult to find treatment options that are simple, non-invasive, and effective. . . until now.
Our next-gen medtech is designed to bring hope to millions of people suffering from Alzheimer’s and other neurodegenerative diseases.
Phase I Clinical Trials
Phase II Clinical Trials
Phase IIb Clinical Trials
Phase III Clinical Trials
Ready to begin Phase III for Alzheimer's
Are you or your loved one suffering from a neurodegenerative disease? Are your treatment options limited and ineffective? Join our Compassionate Use program and gain access to our clinically tested, breakthrough technology. Compassionate Use allows patients to access treatments that are still in clinical trials.
The Problem
The Cost of Doing Nothing
The cumulative physical, emotional, and financial effect of Central Nervous System (CNS) disorders on patients and their caretakers is utterly devastating. The latest data projects that by 2025, the number of people suffering from Alzheimer’s alone is set to increase by 22%–putting enormous strain on our healthcare system, not to mention the families who care for their aging loved ones.
What does an investment in Kurve Therapeutics mean?
the cognitive aging market
The solution
The ViaNase™ Difference
Researchers and scientists have spent the last 25 years trying and failing to develop effective treatments for brain diseases. The majority of the traditional treatments methods available can’t bypass the blood brain barrier, leaving the majority of the medication behind in the nasal cavity, sinuses, or GI tract. Other methods also can produce a number of undesirable side effects.
ViaNase™ Intelligent Delivery holds the key to overcoming this frustrating obstacle. This modified approach to treating Central Nervous System disorders uses Kurve Therapeutics’ patented Controlled Particle Dispersion technology to deliver medication precisely where it is needed, providing relief and a sense of wellbeing for patients battling brain disease.
01
Reduction in systemic side effects
02
Enhances the opportunity for bioavailability
03
Non-invasive / painless
04
Odorless / tasteless
05
User-friendly
06
Increased patient compliance
07
Convenient / portable
08
Lightweight / pocket-sized
09
Battery powered
10
Fast and easy to administer
The Proof
Thoroughly Vetted
Kurve Therapeutics’ revolutionary treatment system is featured in 18 peer-reviewed publications by
leading institutions such as:
clinical trials
Rigorously Tested
We hold to the highest levels of transparency and integrity when it comes to sharing the results of our ongoing clinical trial phase. So far, we’ve met our endpoints in 3 separate clinical trials (Phase 2b) and are cleared to begin Phase 3. Here’s the latest trials we’ve participated in where our next-generation technology was the device of choice:
*Clinical trial reports available upon request
The Opportunity
Here’s where you come in.
In 2022, Kurve Therapeutics filed a Regulation A offering with the SEC. This means we can officially offer investment opportunities for the general public to partner with us as we continue to conduct clinical studies. If these studies prove successful–and all indications are favorable that they will–we will officially move into the next stages of product development and launch.
1 billion people around the world suffer from neurological disorders. And every 3 seconds, someone in the world develops dementia.
If dementia were a country, it would have a $1.3 trillion market size and the 14th largest economy in the world.
Our mission is to break new ground in the treatment of brain disorders and bring hope to those suffering with limited or ineffective treatment options.
The offering
Shape The Future With Us
It’s simple. With your partnership, we have the unprecedented opportunity to change the lives of millions of people battling Alzheimer’s disease and give their families the best gift of all: peace of mind.
When you invest in Kurve Therapeutics, you aren’t just investing in winning against Alzheimer’s — you and your loved ones will benefit from treatment for all the different neurodegenerative disease states we aim to heal, including MS, Parkinson’s, Lewy Body Dementia, PTSD, and more.
$50M
Total Filing Raise
$580
Minimum Investment
$5.80
Price Per Share
Video Introduction
Kurve is at the forefront of a new era of central nervous system disorder treatments.
About Kurve Therapeutics
Our Mission and Vision
To put it simply: we do this because we can and because we have to.
Our mission is to help as many people as we possibly can in their fight with neurodegenerative disorders. Our hope is that these complex debilitating disorders may have a solution when paired with the right medication and the right technology. Our goal is to enhance the quality of life for patients and provide a solution where their past treatments have failed them–to give people a renewed sense of hope for the future.
The Team Behind Kurve
Meet Our Medtech Innovators
Marc Giroux
CHAIRMAN & CHIEF EXECUTIVE OFFICER
Mr. Giroux is a 20-year medical industry veteran with involvement in more than 35 human-use clinical trials in addition to pre-clinical work with rodents, larger mammals, and non-human primates (NHPs). He has worked in the development of new technology in medical devices, medical services, and high-end manufacturing. Utilizing his skills in physics and fluid dynamics, he developed the functional specifications behind all of the technology being used in Kurve’s nose-to-brain drug delivery. The intellectual property owned by Kurve has Marc as the lead or sole inventor. In his capacity at Kurve, he has consulted extensively with companies developing new therapies for neurodegenerative diseases with regard to formulation and device compatibility. As co- or lead author, he has published trade journals and peer-reviewed articles. Before taking on the CEO role, Mr. Giroux was a C-level business development executive and Subject Matter Expert on building executive teams.
Glenn Cornett, M.D., Ph.D.
CHIEF SCIENCE OFFICER
Dr. Glenn Cornett is a biotech entrepreneur and advisor. He holds an M.D. with Distinction in Research from the University of Michigan and a Ph.D. in neuroscience from UCLA. He has spent the past decade developing drugs for psychiatric and neurological indications.
Tom S. McDowell
CHIEF OPERATING OFFICER
Mr. McDowell is a skilled and accomplished COO with forty years of experience in accounting, financial reporting, investment banking, and mergers & acquisitions for established and start-up companies. Tom has consulted with over 25 startups and early-stage companies in the software, telecommunications, financial management, retail, manufacturing, consulting and distribution industries.